Emel Aygören-Pürsün
University Hospital Frankfurt - Goethe University, Frankfurt, Germany · University Hospital Frankfurt Goethe University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Emel Aygören-Pürsün as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:51 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05047185 · Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type IIPharvaris Netherlands B.V. · terminated · Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II · principal investigator
- Ph2NCT02870972 · Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary AngioedemaBioCryst Pharmaceuticals · completed · Hereditary Angioedema (HAE) · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:51 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 12:51 UTC. The ranking covers the 200 most relevant of 31 PubMed records, and a shared surname and initials can bring in a namesake. All 31 on PubMed
- Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial.J Allergy Clin Immunol · 2021138 citationsRCR 11.7
- 120 citationsRCR 15.0
- C1-inhibitor concentrate for individual replacement therapy in patients with severe hereditary angioedema refractory to danazol prophylaxis.Transfusion · 200986 citationsRCR 3.4
- Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema.N Engl J Med · 201884 citationsRCR 4.0
- Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks.J Allergy Clin Immunol Pract · 201971 citationsRCR 4.7
- Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks.N Engl J Med · 202465 citationsRCR 12.5
- CRISPR-Based Therapy for Hereditary Angioedema.N Engl J Med · 202555 citationsRCR 12.7
- Risk of angioedema following invasive or surgical procedures in HAE type I and II--the natural history.Allergy · 201354 citationsRCR 2.5
- Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2).J Allergy Clin Immunol Pract · 202153 citationsRCR 4.2
- 49 citationsRCR 1.9